IL307868A - Compounds for use in the treatment of hyperproliferative disorders - Google Patents
Compounds for use in the treatment of hyperproliferative disordersInfo
- Publication number
- IL307868A IL307868A IL307868A IL30786823A IL307868A IL 307868 A IL307868 A IL 307868A IL 307868 A IL307868 A IL 307868A IL 30786823 A IL30786823 A IL 30786823A IL 307868 A IL307868 A IL 307868A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- thiazol
- indol
- methyl
- acetamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 19
- 230000003463 hyperproliferative effect Effects 0.000 title claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 62
- -1 C 1-4-alkyl Chemical group 0.000 claims 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- IDBDFZFJOFJNPY-UHFFFAOYSA-N 2-imidazo[2,1-b][1,3]thiazol-6-yl-n-[4-(2-methyl-1h-indol-3-yl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC=C2C(C=3N=C(NC(=O)CC=4N=C5SC=CN5C=4)SC=3)=C(C)NC2=C1 IDBDFZFJOFJNPY-UHFFFAOYSA-N 0.000 claims 2
- JOGQECBGGWGCJS-UHFFFAOYSA-N 3-(1H-indol-3-yl)-N-[4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]propanamide Chemical compound C1=CC=C2C(CCC(=O)NC=3SC=C(N=3)C=3C4=CC=CC=C4NC=3C)=CNC2=C1 JOGQECBGGWGCJS-UHFFFAOYSA-N 0.000 claims 2
- MNBQOGHQUOTRBI-UHFFFAOYSA-N CC(C(N(C)C1=NC(C2=C(C)NC3=CC=CC=C23)=CS1)=O)C1=CN(C=CS2)C2=N1 Chemical compound CC(C(N(C)C1=NC(C2=C(C)NC3=CC=CC=C23)=CS1)=O)C1=CN(C=CS2)C2=N1 MNBQOGHQUOTRBI-UHFFFAOYSA-N 0.000 claims 2
- LVGQBVQRQDXSHF-UHFFFAOYSA-N CC(NC1=C2)=C(C3=CSC(NC(CC4=CN(C=CS5)C5=N4)=O)=N3)C1=CC=C2F Chemical compound CC(NC1=C2)=C(C3=CSC(NC(CC4=CN(C=CS5)C5=N4)=O)=N3)C1=CC=C2F LVGQBVQRQDXSHF-UHFFFAOYSA-N 0.000 claims 2
- XJOHRKQFLSPSHR-UHFFFAOYSA-N CC(NC1=CC=CC=C11)=C1C1=C(C)SC(NC(CC2=CN(C=CS3)C3=N2)=O)=N1 Chemical compound CC(NC1=CC=CC=C11)=C1C1=C(C)SC(NC(CC2=CN(C=CS3)C3=N2)=O)=N1 XJOHRKQFLSPSHR-UHFFFAOYSA-N 0.000 claims 2
- UVVVTCOLTKGWLG-UHFFFAOYSA-N CC(NC1=CC=CC=C11)=C1C1=C(F)SC(NC(CC2=CN(C=CS3)C3=N2)=O)=N1 Chemical compound CC(NC1=CC=CC=C11)=C1C1=C(F)SC(NC(CC2=CN(C=CS3)C3=N2)=O)=N1 UVVVTCOLTKGWLG-UHFFFAOYSA-N 0.000 claims 2
- YKBBMFSQWGNPPH-UHFFFAOYSA-N CC(S1)=CN2C1=NC(CC(NC1=NC(C3=C(C)NC4=CC=CC=C34)=CS1)=O)=C2 Chemical compound CC(S1)=CN2C1=NC(CC(NC1=NC(C3=C(C)NC4=CC=CC=C34)=CS1)=O)=C2 YKBBMFSQWGNPPH-UHFFFAOYSA-N 0.000 claims 2
- ITIWQPRNCJSDPR-UHFFFAOYSA-N CC1=C(C2=COC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=COC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC=CC=C2N1 ITIWQPRNCJSDPR-UHFFFAOYSA-N 0.000 claims 2
- NPRCJUQAOZEYHH-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC(C3=C4)=CNC3=CC=C4F)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC(C3=C4)=CNC3=CC=C4F)=O)=N2)C2=CC=CC=C2N1 NPRCJUQAOZEYHH-UHFFFAOYSA-N 0.000 claims 2
- CNZQKPDGTGILMB-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC(C3=C4)=CNC3=CC=C4O)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC(C3=C4)=CNC3=CC=C4O)=O)=N2)C2=CC=CC=C2N1 CNZQKPDGTGILMB-UHFFFAOYSA-N 0.000 claims 2
- CHHAMDNJEXEPTM-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC(C3=C4)=CNC3=CC=C4OC)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC(C3=C4)=CNC3=CC=C4OC)=O)=N2)C2=CC=CC=C2N1 CHHAMDNJEXEPTM-UHFFFAOYSA-N 0.000 claims 2
- RMGDNQLJYGIFBW-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CC(Br)=CS3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CC(Br)=CS3)=O)=N2)C2=CC=CC=C2N1 RMGDNQLJYGIFBW-UHFFFAOYSA-N 0.000 claims 2
- AZJROIGJIKGFCR-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CC(C=CC=C4)=C4O3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CC(C=CC=C4)=C4O3)=O)=N2)C2=CC=CC=C2N1 AZJROIGJIKGFCR-UHFFFAOYSA-N 0.000 claims 2
- CRZCZRGSFYNNBF-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CC4=CC=CC=C4N3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CC4=CC=CC=C4N3)=O)=N2)C2=CC=CC=C2N1 CRZCZRGSFYNNBF-UHFFFAOYSA-N 0.000 claims 2
- XDUMJTPLBZMVAJ-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CN(C)C4=CC=CC=C34)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CN(C)C4=CC=CC=C34)=O)=N2)C2=CC=CC=C2N1 XDUMJTPLBZMVAJ-UHFFFAOYSA-N 0.000 claims 2
- WKDKLNBAOUYOIM-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CN(C=C(C=C4)F)C4=N3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CN(C=C(C=C4)F)C4=N3)=O)=N2)C2=CC=CC=C2N1 WKDKLNBAOUYOIM-UHFFFAOYSA-N 0.000 claims 2
- RZFFLWVRNXPJQM-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC(N)=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC(N)=CC=C2N1 RZFFLWVRNXPJQM-UHFFFAOYSA-N 0.000 claims 2
- RYZODVQMJCFVST-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC(OC)=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC(OC)=CC=C2N1 RYZODVQMJCFVST-UHFFFAOYSA-N 0.000 claims 2
- KIFKHVHNYDBQNZ-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC([N+]([O-])=O)=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CN(C=CS4)C4=N3)=O)=N2)C2=CC([N+]([O-])=O)=CC=C2N1 KIFKHVHNYDBQNZ-UHFFFAOYSA-N 0.000 claims 2
- GVYHQRCGRWHASH-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CNC4=CC(Cl)=CC=C34)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CNC4=CC(Cl)=CC=C34)=O)=N2)C2=CC=CC=C2N1 GVYHQRCGRWHASH-UHFFFAOYSA-N 0.000 claims 2
- OFOSQCGPIKARPR-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CNC4=CC=CC=C34)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CNC4=CC=CC=C34)=O)=N2)C2=CC=CC=C2N1 OFOSQCGPIKARPR-UHFFFAOYSA-N 0.000 claims 2
- PWARUKNSNOVTDN-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CNC=N3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CNC=N3)=O)=N2)C2=CC=CC=C2N1 PWARUKNSNOVTDN-UHFFFAOYSA-N 0.000 claims 2
- YOBYRGFRBBFUQD-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=CSC4=NC=CN34)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=CSC4=NC=CN34)=O)=N2)C2=CC=CC=C2N1 YOBYRGFRBBFUQD-UHFFFAOYSA-N 0.000 claims 2
- HZJXPROVZLZGTQ-UHFFFAOYSA-N CC1=C(C2=CSC(NC(CC3=NC(C=CC=C4)=C4O3)=O)=N2)C2=CC=CC=C2N1 Chemical compound CC1=C(C2=CSC(NC(CC3=NC(C=CC=C4)=C4O3)=O)=N2)C2=CC=CC=C2N1 HZJXPROVZLZGTQ-UHFFFAOYSA-N 0.000 claims 2
- BMJHRBBKVWNMQW-UHFFFAOYSA-N CC1=C(CC(NC2=NC(C3=C(C)NC4=CC=CC=C34)=CS2)=O)SC2=C1C=CC=C2 Chemical compound CC1=C(CC(NC2=NC(C3=C(C)NC4=CC=CC=C34)=CS2)=O)SC2=C1C=CC=C2 BMJHRBBKVWNMQW-UHFFFAOYSA-N 0.000 claims 2
- FDARGIXVWGRVQR-UHFFFAOYSA-N CC1=CC=C2NC=C(C3=CSC(NC(CC4=CN(C=CS5)C5=N4)=O)=N3)C2=C1 Chemical compound CC1=CC=C2NC=C(C3=CSC(NC(CC4=CN(C=CS5)C5=N4)=O)=N3)C2=C1 FDARGIXVWGRVQR-UHFFFAOYSA-N 0.000 claims 2
- ZRJNPVQQLYVRDF-UHFFFAOYSA-N CC1=CSC2=NC(CC(NC3=NC(C4=C(C)NC5=CC=CC=C45)=CS3)=O)=CN12 Chemical compound CC1=CSC2=NC(CC(NC3=NC(C4=C(C)NC5=CC=CC=C45)=CS3)=O)=CN12 ZRJNPVQQLYVRDF-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- YRIJACZWRDOSBS-UHFFFAOYSA-N O=C(CC1=CN(C=CS2)C2=N1)NC1=NC(C2=CNC3=CC=CC(Br)=C23)=CS1 Chemical compound O=C(CC1=CN(C=CS2)C2=N1)NC1=NC(C2=CNC3=CC=CC(Br)=C23)=CS1 YRIJACZWRDOSBS-UHFFFAOYSA-N 0.000 claims 2
- WFRZZZBXKCOVCE-UHFFFAOYSA-N [O-][N+](C1=CC=C2NC=C(C3=CSC(NC(CC4=CN(C=CS5)C5=N4)=O)=N3)C2=C1)=O Chemical compound [O-][N+](C1=CC=C2NC=C(C3=CSC(NC(CC4=CN(C=CS5)C5=N4)=O)=N3)C2=C1)=O WFRZZZBXKCOVCE-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Chemical group 0.000 claims 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382343.8A EP4079304A1 (en) | 2021-04-21 | 2021-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
| PCT/EP2022/060579 WO2022223704A1 (en) | 2021-04-21 | 2022-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307868A true IL307868A (en) | 2023-12-01 |
Family
ID=75674747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307868A IL307868A (en) | 2021-04-21 | 2022-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240208998A1 (enExample) |
| EP (2) | EP4079304A1 (enExample) |
| JP (1) | JP2024515705A (enExample) |
| KR (1) | KR20240013112A (enExample) |
| CN (1) | CN117320715A (enExample) |
| AU (1) | AU2022260529A1 (enExample) |
| BR (1) | BR112023021959A2 (enExample) |
| CA (1) | CA3216090A1 (enExample) |
| IL (1) | IL307868A (enExample) |
| MX (1) | MX2023012457A (enExample) |
| WO (1) | WO2022223704A1 (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2609912T3 (es) * | 2007-06-22 | 2017-04-25 | Hydra Biosciences, Inc. | Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 |
-
2021
- 2021-04-21 EP EP21382343.8A patent/EP4079304A1/en not_active Withdrawn
-
2022
- 2022-04-21 CN CN202280035450.7A patent/CN117320715A/zh active Pending
- 2022-04-21 BR BR112023021959A patent/BR112023021959A2/pt unknown
- 2022-04-21 US US18/556,456 patent/US20240208998A1/en active Pending
- 2022-04-21 EP EP22723682.5A patent/EP4326262A1/en active Pending
- 2022-04-21 JP JP2023564537A patent/JP2024515705A/ja active Pending
- 2022-04-21 KR KR1020237040063A patent/KR20240013112A/ko active Pending
- 2022-04-21 WO PCT/EP2022/060579 patent/WO2022223704A1/en not_active Ceased
- 2022-04-21 IL IL307868A patent/IL307868A/en unknown
- 2022-04-21 MX MX2023012457A patent/MX2023012457A/es unknown
- 2022-04-21 AU AU2022260529A patent/AU2022260529A1/en active Pending
- 2022-04-21 CA CA3216090A patent/CA3216090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024515705A (ja) | 2024-04-10 |
| WO2022223704A1 (en) | 2022-10-27 |
| MX2023012457A (es) | 2023-11-22 |
| EP4079304A1 (en) | 2022-10-26 |
| CA3216090A1 (en) | 2022-10-27 |
| KR20240013112A (ko) | 2024-01-30 |
| AU2022260529A1 (en) | 2023-11-09 |
| US20240208998A1 (en) | 2024-06-27 |
| BR112023021959A2 (pt) | 2023-12-26 |
| CN117320715A (zh) | 2023-12-29 |
| EP4326262A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1891042B1 (en) | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their therapeutic use on the central nervous system | |
| RU2460732C2 (ru) | Производные 2-аза-бицикло[3.1.0.]гексана в качестве антагонистов рецептора орексина | |
| CA2146961C (en) | Heterobicyclic sulfonamide and sulfonic ester derivatives | |
| CN101677563B (zh) | 5,6-二氢-1h-吡啶-2-酮化合物 | |
| RU95109927A (ru) | Производные 5-арилиндола и их применение в качестве агонистов серотонина (5-ht*00i) | |
| BRPI0710527A2 (pt) | compostos de pirrolo-e tiazolo-piridina e métodos para sua utilização | |
| HRP950023A2 (en) | Tetracyclic derivatives, process of preparation and use | |
| ES544349A0 (es) | Un procedimiento para la preparacion de derivados de benzofurano. | |
| CN114080389B (zh) | Nrf2活性化化合物 | |
| CA2433417A1 (en) | Novel 1,2-diphenylethene derivatives for treatment of immune diseases | |
| JP2018536678A (ja) | セフェム系化合物、それらの生成および使用 | |
| Gandhi et al. | Synthetic aspects and Biological Studies of some Heterocycles. | |
| JP2003313176A (ja) | アミノアゾール誘導体 | |
| DK1216245T3 (da) | Farmaceutisk aktive sulfonylhydrazidderivater | |
| DK160098B (da) | Tricycliske oxindolcarboxamid-derivater | |
| IL307868A (en) | Compounds for use in the treatment of hyperproliferative disorders | |
| PL176471B1 (pl) | Nowe pochodne (1-heteroazolilo-1-heterocyklo)alkanów, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca | |
| ES2249718T3 (es) | Derivados de dibenzodiazepina, su preparacion y uso. | |
| KR20020002394A (ko) | 비만증 예방 또는 치료용 약제를 제조하기 위한,폴리사이클릭 2-아미노-티아졸계의 용도 | |
| HU902976D0 (en) | Process for the preparation of heterocyclic guanidine derivatives | |
| JP2024515705A5 (enExample) | ||
| EP1709040A2 (en) | Five-membered heterocyclic compounds as inhibitors of src family protein kinase | |
| CN114222574B (zh) | 抑制usp36 | |
| KR940009186A (ko) | 이미다조피리딘 | |
| KR101646725B1 (ko) | ＰＴＰσ 매개성 질환 치료 또는 예방용 약학적 조성물 |